Related Experiment Videos
Rosiglitazone-induced granulomatous hepatitis.
Manish Dhawan1, Radheshyam Agrawal, Jan Ravi
1Department of Gastroenterology, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, PA 15212, U.S.A.
Journal of Clinical Gastroenterology
|April 18, 2002
Summary
Rosiglitazone, a diabetes drug, may cause granulomatous hepatitis. Regular liver function tests are recommended for patients taking this medication to monitor for potential liver injury.
Area of Science:
- Hepatology
- Endocrinology
- Pharmacology
Background:
- Granulomatous hepatitis is a liver condition with diverse etiologies.
- Drug-induced liver injury is a significant concern in clinical practice.
- Oral hypoglycemic agents, including thiazolidinediones like rosiglitazone, are used for type II diabetes management.
Observation:
- Rosiglitazone, a thiazolidinedione, has shown no hepatotoxicity in premarketing studies.
- However, isolated case reports suggest a potential link between rosiglitazone and acute hepatocellular injury.
- This report details a case of granulomatous hepatitis specifically associated with rosiglitazone use.
Findings:
- The presented case demonstrates granulomatous hepatitis in a patient treated with rosiglitazone.
- This finding adds to the limited but growing evidence implicating rosiglitazone in liver injury.
Implications:
- Clinicians should consider rosiglitazone as a potential cause of granulomatous hepatitis.
- Regular monitoring of liver function tests is crucial for patients prescribed rosiglitazone.
- Further research may be warranted to fully elucidate the hepatotoxic potential of rosiglitazone.